What this evidence supports
PROSPR is funding a GPER agonist program intended to test aging-related outcomes.
What it does not establish
The project is investigational; benefit on aging or healthspan outcomes has not been established.
Record details
- Source authority
- ARPA-H
- Evidence level
- E5
- Directness
- 5/5
- Recency
- 4/5
- Decision relevance
- 4/5
- Date
- 2026-02-24
Primary source
Related intelligence
PROSPR funds GPER agonist development to test improvement in aging outcomes